Nevertheless, previous studies have shown that plasma detection of RAS mutations has a high level of concordance with tissue biopsy results and a similar predictive level for benefit of anti-EGFR treatment as standard tumor tissue testing19,20. This evidence concerns the gene EGFR and neoplasm.